Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
The purpose of this study is to Investigate the Absorption, Metabolism and Excretion of \[14C\] Anlotinib in Patients With Advanced Cancer patients.
Advanced Solid Tumors
DRUG: Anlotinib and 14C-labeled Anlotinib
Cumulative excretion of 14C-labeled Anlotinib (radioactivity in urine), up to 10 Days(endpoint when the two consecutive time points of cumulative excretion <1%)|Cumulative excretion of 14C-labeled Anlotinib (radioactivity in feces), up to 10 Days(endpoint when the two consecutive time points of cumulative excretion <1%)|Excretion rate of 14C-labeled Anlotinib (radioactivity in urine), up to 10 Days(endpoint when the two consecutive time points of cumulative excretion <1%)|Excretion rate of 14C-labeled Anlotinib (radioactivity in feces), up to 10 Days (endpoint when the two consecutive time points of cumulative excretion <1%)|Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Peak Plasma Concentration(Cmax), Peak Plasma Concentration(Cmax),Cmax in ng/mL,, up to 10 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)|Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Peak time（Tmax）, Peak time（Tmax）,Tmax in h., up to 10 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)|Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood):Half life（t1/2）, Half life（t1/2）,t1/2 in h., up to 10 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)|Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood): Area under the plasma concentration versus time curve (AUC), Area under the plasma concentration versus time curve (AUC), AUC in ng.h/mL., up to 10 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)|Pharmacokinetics of 14C-labeled Anlotinib (Radioactivity in whole blood): Clearance（CL）, Clearance（CL）,CL in L/h., up to 10 Days (endpoint when the two consecutive time points of blood drug concentration <150 DPM/mL)
Metabolite identification of Anlotinib in plasma, urine and feces, up to 10 Days(endpoint when the two consecutive time points of cumulative excretion <1%)
The purpose of this study is to Investigate the Absorption, Metabolism and Excretion of \[14C\] Anlotinib in Patients With Advanced Cancer patients.